Marburg virus was first recognized in 1967, when outbreaks of hemorrhagic fever occurred simultaneously in laboratories in Marburg and Frankfurt, Germany and in Belgrade, Yugoslavia (now Serbia). Marburg hemorrhagic fever (Marburg HF) is a rare but severe hemorrhagic fever which affects both humans and non-human primates. Marburg HF is caused by Marburg virus, a genetically unique zoonotic (or, animal-borne) RNA virus of the filovirus family.
Signs and Symptoms
After an incubation period of 5-10 days, symptom onset is sudden and marked by fever, chills, headache, and myalgia. Around the fifth day after the onset of symptoms, a maculopapular rash, most prominent on the trunk (chest, back, stomach), may occur. Nausea, vomiting, chest pain, a sore throat, abdominal pain, and diarrhea may then appear.
Symptoms become increasingly severe and can include jaundice, inflammation of the pancreas, severe weight loss, delirium, shock, liver failure, massive hemorrhaging, and multi-organ dysfunction.
DelveInsight’s, “Marburg Virus Disease Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Marburg Virus Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Some of the Marburg Virus Disease Companies are:
Request for free Sample Report: https://www.delveinsight.com/sample-request/marburg-virus-disease-pipeline-insight
DelveInsight’s Marburg Virus Disease report covers around 6+ products under different phases of clinical development like
Some of the Marburg Virus Disease Therapies are:
Current Marburg Virus Disease Treatment Scenario and Marburg Virus Disease Emerging Therapies:
Table of Contents:
Introduction
Executive Summary
Marburg Virus Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Marburg Virus Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Mid Stage Products (Phase II)
MVA-BN filovirus vaccine: Bavarian Nordic
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Galidesivir: BioCryst Pharmaceuticals
Inactive Products
Marburg Virus Disease Key Companies
Marburg Virus Disease Key Products
Marburg Virus Disease- Unmet Needs
Marburg Virus Disease- Market Drivers and Barriers
Marburg Virus Disease- Future Perspectives and Conclusion
Marburg Virus Disease Analyst Views
Appendix
Request for Detailed TOC: https://www.delveinsight.com/sample-request/marburg-virus-disease-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/marburg-virus-disease-pipeline-insight